Clinical trials: Hospitalized COVID-19
SARS-CoV Infection
Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19
As part of the Coronavirus Infectious Disease 2019 (COVID19) pandemic, the hospital care system is facing a major strain. Patients with SARS-Cov2 (severe acute respiratory syndrome coronavirus 2 ) infection can worsen very…
- Trial name
- SITCOV (NCT04730661)
- Testing
- Sit to stand test
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Rouen
COVID-19
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19.
- Trial name
- COMMUNITY (NCT04590586)
- Testing
- Standard of care, Apremilast, Lanadelumab
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Covid19
A Simple Approach to Prevent Hospitalization for COVID-19 Patients
The newly recognised disease COVID-19 is caused by the Severe-Acute-Respiratory-Syndrome Coronavirus 2 (SARS-CoV-2), which rapidly spread globally in late 2019, reaching pandemic proportions.
- Trial name
- COVER2 (NCT04854824)
- Testing
- Recommended treatment schedule, Control treatment schedule
- Where
- 2 sites in Italy
- Volunteers
- 216 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
COVID-19, Acute Respiratory Distress Syndrome
DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia
The aim of this study is to evaluate the efficacy of dexamethasone in hospitalized adults with COVID-19 pneumonia who do not require supplementary oxygen on admission, but have high risk of developing acute respiratory distress…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- EARLYDEXCoV2 (NCT04836780)
- Testing
- Dexamethasone
- Where
- 3 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Hospital Universitario Infanta Leonor
Sars-CoV2
The Natural History of Hospitalized COVID-19 Patients
This is an observational study. The aim is to describe the natural history and clinical evolution over time of hospitalized patients affected by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) infection, including…
- Trial name
- STORM (NCT04424992)
- Testing
- Observational cohort study on the natural history of hospitalized SARS-COV-2 patients.
- Where
- Italy
- Volunteers
- 1,433 people
- Sponsor
- University of Milano Bicocca
COVID-19
Anti-inflammatory Drug Algorithm for COVID-19 Home Treatment
The newly recognised disease COVID-19 is caused by the Severe-AcuteRespiratory-Syndrome Coronavirus 2 (SARS-CoV-2), which rapidly spread globally in late 2019, reaching pandemic proportions.
- Trial name
- COVER3 (NCT05249790)
- Testing
- Recommended treatment schedule, Usual care
- Sponsor
- Mario Negri Institute for Pharmacological Research
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
SARS-CoV-2 Pneumonia
Predictors of Respiratory Failure in SARS-Cov-2 Infection
The emergence of SARS-CoV-2 is currently engaging and consuming most of resources of efficient healthcare systems in Europe, and several hospitals are currently experiencing a shortage of ICU beds for critically-ill patients with…
- Trial name
- NCT04316949
- Where
- Italy
- Volunteers
- 350 people
- Sponsor
- University of Bologna
Coronavirus Infection
STerOids in COVID-19 Study
At the time of writing (3/4/2020), close to a million people have been infected by the SARS-CoV-2 coronavirus around the world. The severe clinical condition that leads to deaths is now called CoVID-19.
- Trial name
- STOIC (NCT04416399)
- Testing
- Budesonide dry powder inhaler
- Where
- United Kingdom
- Volunteers
- 146 people
- Sponsor
- University of Oxford
COVID-19 Pandemic
Physiotherapy in Mutated COVID-19 Patients
The prospective study was conducted at a single location within the COVID-19 department of a city hospital. The study included COVID-19 patients who were hospitalized in the COVID-19 service and consulted for physiotherapy, were…
- Trial name
- NCT05874076
- Testing
- Physiotherapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Giresun University
Covid19
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.
- Trial name
- NCT04707534
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Oklahoma
COVID-19
Convalescent Plasma in Hospitalized COVID-19 Patients
The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion.
- Trial name
- NCT05157165
- Testing
- Convalescent plasma
- Sponsor
- Azienda Socio Sanitaria Territoriale di Mantova
Covid-19
Long COVID Kids DK - Investigating Long-term Covid-19
During the COVID-19 pandemic children have been perceived as a group not being especially affected, with less being infected, low symptom burden and low mortality.
- Trial name
- NCT04786353
- Testing
- LongCOVIDkidsDK
- Where
- Denmark
- Volunteers
- 330,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in…
- Trial name
- XACT (NCT04640181)
- Testing
- Enoxaparin, Rivaroxaban
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. David's HealthCare
COVID-19 Pneumonia
Tele-rehabilitation Program After Hospitalization for COVID-19
Given the number of hospitalized subjects for COVID-19, the difficulties linked to the infectious risk, and the high cost of managing departments for COVID-19 subjects, the execution of home rehabilitation programs, in the form…
- Trial name
- NCT04821934
- Testing
- TR, TSu
- Where
- 2 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Covid19
Institutional Registry on Outpatient and Hospitalized COVID-19 Infected Patients
Creation of an Institutional Registry system for patients with confirmed COVID-19 infection with the collection of epidemiological data, risk factors, diagnosis, prognoses, treatment, follow-up and survival.
- Trial name
- IRCIP (NCT04839107)
- Where
- Argentina
- Volunteers
- 20,000 people
- Sponsor
- Hospital Italiano de Buenos Aires
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
COVID-19
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
Tocilizumab is an effective treatment for severe coronavirus disease 2019 (Covid-19) pneumonia and related inflammation. Given limited global supplies, clarification of the optimal tocilizumab dose is critical.
- Trial name
- COVIDOSE-2 (NCT04479358)
- Testing
- Tocilizumab, Standard of Care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Infections, Coronavirus
Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
- Trial name
- NCT04542226
- Testing
- Polyoxidonium
- Where
- 5 sites in Belarus, Russia
- Volunteers
- 81 people
- Sponsor
- NPO Petrovax
COVID-19
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting.
- Trial name
- ROCOVI (NCT05196477)
- Testing
- Olokizumab, Standard therapy
- Where
- 6 sites in Russia
- Volunteers
- 3,087 people
- Sponsor
- R-Pharm